Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AER 003 - Aerium Therapeutics

Next Previous
X
Search
Drug Profile

AER 003 - Aerium Therapeutics

Alternative Names: AER-003 - Aerium Therapeutics

Latest Information Update: 17 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Centre Hospitalier Universitaire Vaudois
  • Developer Aerium Therapeutics
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 13 Oct 2023 Preclinical trials in COVID-2019 infections in USA (Parenteral)
  • 24 Mar 2023 Aerium Therapeutics enters into a collaboration and licensing agreement with Centre Hospitalier Universitaire Vaudois and Swiss Federal Institute of Technology to develop SARS-CoV-2 monoclonal antibodies for treatment of COVID-2019 infections
  • 24 Mar 2022 Pharmacodynamics data from preclinical trials in COVID-2019 infections released by Aerium Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top